Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) [Phase 2]

View source ↗

Summary

A Phase 2 trial (ENHANCE) is evaluating a triple regimen of BRII-179, BRII-835, and PEG-IFNα for chronic hepatitis B infection, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• BRII-179
• BRII-835
• PEG-IFNα (pegylated interferon alfa)

Snippet

Sponsor: Brii Biosciences Limited | Conditions: Chronic Hepatitis B Virus (HBV) Infection | Phase 2 | Status: RECRUITING